Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Colchicine | Review

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)

Authors: Georges El Hasbani, Ali Jawad, Imad Uthman

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Familial Mediterranean Fever (FMF), an autoinflammatory disease, is characterized by self-limited inflammatory attacks of fever and polyserositis along with high acute phase response. Although colchicine remains the mainstay in treatment, intolerance and resistance in a certain portion of patients have been posing a problem for physicians.

Main body

Like many autoimmune and autoinflammatory diseases, many colchicine-resistant or intolerant FMF cases have been successfully treated with biologics. In addition, many studies have tested the efficacy of biologics in treating FMF manifestations.

Conclusion

Since carriers of FMF show significantly elevated levels of serum TNF alpha, IL-1, and IL-6, FMF patients who failed colchicine were successfully treated with anti IL-1, anti IL-6, or TNF inhibitors drugs. It is best to use colchicine in combination with biologics.
Literature
1.
2.
El-Shanti H, Majeed HA, El-Khateeb M. Familial mediterranean fever in Arabs. Lancet. 2006;367(9515):1016–24.CrossRefPubMed
3.
Tunca M, Ozdogan H, Kasapcopur O, Yalcinkaya F, Ozen S, Topaloglu R, et al. Familial mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1–11.CrossRef
4.
Ben-Chetrit E, Touitou I. Familial mediterranean fever in the world. Arthritis Care Res. 2009;61(10):1447–53.
5.
Bernot A, Clepet C, Dasilva C, Devaud C, Petit JL, Caloustian C, et al. A candidate gene for familial mediterranean fever. Nat Genet. 1997;7(8):1317–25.
6.
Aksentijevich I, Centola M, Deng Z, Sood R, Balow J, Wood G, et al. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797–807.
7.
Georgin-Lavialle S, Hentgen V, Stankovic Stojanovic K, Bachmeyer C, Rodrigues F, Savey L, et al. Familial mediterranean fever. Rev Med Interne. 2018;39(4):240–55.
8.
9.
Lidar M, Yaqubov M, Zaks N, Ben-Horin S, Langevitz P, Livneh A. The prodrome: a prominent yet overlooked pre-attack manifestation of familial mediterranean fever. J Rheumatol. 2006;33(6):1089–92.PubMed
10.
Sohar E, Gafni J, Pras M, Heller H. Reviews familial mediterranean fever* a Suruey of 470 cases and review of the literature. Am J Med. 1967;43(2):227–53.
11.
Kees S, Langevitz P, Zemer D, Padeh S, Pras M, Livneh A. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). Q J Med. 1997;90(10):643–7.CrossRef
12.
Lidar M, Kedem R, Mor A, Levartovsky D, Langevitz P, Livneh A. Arthritis as the sole episodic manifestation of familial Mediterranean fever. J Rheumatol. 2005;32(5):859–62.PubMed
13.
Lidar M, Doron A, Barzilai A, Feld O, Zaks N, Livneh A, et al. Erysipelas-like erythema as the presenting feature of familial Mediterranean fever. J Eur Acad Dermatol Venereol. 2013;27(7):912–5.CrossRefPubMed
14.
Kukuy O, Livneh A, Ben-David A, Kopolovic J, Volkov A, Shinar Y, et al. Familial Mediterranean fever (FMF) with proteinuria: clinical features, histology, predictors, and prognosis in a cohort of 25 patients. J Rheumatol. 2013;40(12):2083–7.CrossRefPubMed
15.
Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S, Emmungil H, et al. Amyloidosis and its related factors in turkish patients with familial mediterranean fever: a multicentre study. Rheumatol U K. 2014;53(4):741–5.CrossRef
16.
van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med. 2005;5(3):87–98.CrossRefPubMed
17.
Stoffels M, Szperl A, Simon A, Netea MG, Plantinga TS, Van Deuren M, et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis. 2014;73(2):455–61.CrossRefPubMed
18.
de Torre-Minguela C, del Castillo PM, Pelegrín P. The NLRP3 and pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol. 2017;8:43.PubMedPubMedCentral
19.
Shinar Y, Obici L, Aksentijevich I, Bennetts B, Austrup F, Ceccherini I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012;71(10):1599–605.CrossRefPubMed
20.
Majeed HA, El-Shanti H, Al-Khateeb MS, Rabaiha ZA. Genotype/phenotype correlations in Arab patients with familial mediterranean fever. Semin Arthritis Rheum. 2002;31(6):371–6.CrossRefPubMed
21.
Giancane G, Haar NMT, Wulffraat N, Vastert SJ, Barron K, Hentgen V, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015;74(4):635–41.CrossRefPubMed
22.
Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10):1879–85.CrossRefPubMed
23.
Demirkaya E, Saglam C, Turker T, Koné-Paut I, Woo P, Doglio M, et al. Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: results from a multicenter international registry. J Rheumatol. 2016;43(1):154–60.CrossRefPubMed
24.
Alghamdi M. Familial Mediterranean fever, review of the literature. Clin Rheumatol. 2017;36(8):1707–13.CrossRefPubMed
25.
Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–51.CrossRefPubMed
26.
Dinarello CA, Wolfe SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial Mediterranean fever. N Engl J Med. 1974;291(18):934–7.CrossRefPubMed
27.
Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004;428(6979):198–202.CrossRefPubMed
28.
Taskiran EZ, Cetinkaya A, Balci-Peynircioglu B, Akkaya YZ, Yilmaz E. The effect of colchicine on pyrin and pyrin interacting proteins. J Cell Biochem. 2012;113(11):3536–46.CrossRefPubMed
29.
Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron. 1992;60(4):418–22.CrossRefPubMed
30.
Jayaprakash V, Ansell G, Galler D. Colchicine overdose: the devil is in the detail. N Z Med J. 2007;120(1248):U2402.PubMed
31.
Varughese GI, Varghese AI, Tahrani AA. Colchicine: time to rethink [1]. N Z Med J. 2007;120(1249):U2429.PubMed
32.
33.
American Academy of Periatrics - Comitee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93(1):137–50.
34.
Ben-Chetrit E, Ben-Chetrit A, Berkun Y, Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res. 2010;62(2):143–8.CrossRef
35.
Diav-Citrin O, Shechtman S, Schwartz V, Avgil-Tsadok M, Finkel-Pekarsky V, Wajnberg R, et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol. 2010;203(2):144.e1–6.CrossRef
36.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol. 2010;48(5):407–14.CrossRef
37.
Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007;119(2):e474–83.CrossRefPubMed
38.
Barut K, Sahin S, Adrovic A, Sinoplu AB, Yucel G, Pamuk G, et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int. 2018;38(1):67–74.CrossRefPubMed
39.
Kiraz S, Ertenli I, Arici M, Calgüneri M, Haznedaroglu I, Çelik I, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol. 1998;16(6):721–4.PubMed
40.
Terreri MTRA, Bernardo WM, Len CA, da Silva CAA, de Magalhães CMR, Sacchetti SB, et al. Guidelines for the management and treatment of periodic fever syndromes familial Mediterranean fever. Rev Bras Reumatol. 2016;56(1):37–43.CrossRef
41.
Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1–receptor antagonist in the Muckle–Wells syndrome. N Engl J Med. 2003;348(25):2583–4.CrossRefPubMed
42.
Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci U S A. 2006;103(26):9982–7.CrossRefPubMedPubMedCentral
43.
Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med. 2007;146(11):825–6.CrossRefPubMed
44.
Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008;167(6):695–6.CrossRefPubMed
45.
Gattringer R, Lagler H, Gattringer KB, Knapp S, Burgmann H, Winkler S, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Investig. 2007;37(11):912–4.CrossRef
46.
Kuijk LM, Govers AMAP, Hofhuis WJD, Frenkel J. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis. 2007;66(11):1545–6.CrossRefPubMedPubMedCentral
47.
Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med. 2008;66(11):3.
48.
Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine. 2008;75(4):504–5.CrossRefPubMed
49.
Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2009;24(2):676–8.
50.
Petropoulou AD, Robin M, Socié G, Galicier L. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with Anakinra. Transplantation. 2010;90(1):102–3.CrossRefPubMed
51.
Özen S, Bilginer Y, Ayaz NA, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516–8.CrossRefPubMed
52.
Alpay N, Şumnu A, Çalışkan Y, Yazıcı H, Türkmen A, Gül A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int. 2012;32(10):3277–9.CrossRefPubMed
53.
Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 2009;29(2):209.CrossRefPubMed
54.
Hennig S, Bayegan K, Uffmann M, Thalhammer F, Winkler S. Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra—case report and review. Rheumatol Int. 2012;32(6):1801–4.CrossRefPubMed
55.
Stankovic Stojanovic K, Delmas Y, Ureña Torres P, Peltier J, Pelle G, Jéru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27(5):1898–901.CrossRefPubMed
56.
Estublier C, Stankovic Stojanovic K, Bergerot J-F, Broussolle C, Sève P. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Jt Bone Spine Rev Rhum. 2013;80(6):645–9.CrossRef
57.
Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1β biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol. 2013;45(1):117–30.CrossRefPubMed
58.
Celebi ZK, Kucuksahin O, Sengul S, Tuzuner A, Keven K. Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra. Clin Kidney J. 2014;7(2):219–20.CrossRefPubMedPubMedCentral
59.
Mercan R, Turan A, Bitik B, Tufan A, Haznedaroglu S, Goker B. Rapid resolution of protracted febrile myalgia syndrome with anakinra: report of two cases. Mod Rheumatol. 2016;26(3):458–9.PubMed
60.
Sevillano ÁM, Hernandez E, Gonzalez E, Mateo I, Gutierrez E, Morales E, et al. Anakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosis. Nefrología. 2016;36(1):63–6.CrossRefPubMed
61.
Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, et al. Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol Hoboken NJ. 2017;69(4):854–62.CrossRef
62.
Pecher A-C, Igney-Oertel A, Kanz L, Henes J. Treatment of familial Mediterranean fever with anakinra in patients unresponsive to colchicine. Scand J Rheumatol. 2017;46(5):407–9.CrossRefPubMed
63.
İlgen U, Küçükşahin O. Anakinra use during pregnancy: report of a case with familial Mediterranean fever and infertility. Eur J Rheumatol. 2017;4(1):66–7.CrossRefPubMedPubMedCentral
64.
Venhoff N, Voll RE, Glaser C, Thiel J. IL-1-Blockade mit Anakinra in der Schwangerschaft. Z Für Rheumatol. 2018;77(2):127–34.CrossRef
65.
Laskari K, Boura P, Dalekos GN, Garyfallos A, Karokis D, Pikazis D, et al. FRI0497 the Interleukin-1 inhibitor Canakinumab for familial Mediterranean fever: long-term beneficial effect in a cohort of 14 patients. Ann Rheum Dis. 2016;75(Suppl 2):618–9.CrossRef
66.
Babaoglu H, Varan O, Kucuk H, Atas N, Satis H, Salman R, et al. On demand use of anakinra for attacks of familial Mediterranean fever (FMF). Clin Rheumatol. 2019;38(2):577–81.CrossRefPubMed
67.
Hausmann JS. Targeting cytokines to treat autoinflammatory diseases. Clin Immunol. 2018;206:23–32.
68.
Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011;70(7):1347–8.CrossRefPubMed
69.
Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology. 2012;51(6):1041.CrossRefPubMed
70.
Brik R, Butbul-Aviel Y, Lubin S, Dayan EB, Rachmilewitz-Minei T, Tseng L, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol. 2014;66(11):3241–3.CrossRefPubMed
71.
Alpa M, Roccatello D. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther. 2015;9:1983–7.PubMedPubMedCentral
72.
Gül A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17:243.CrossRefPubMedPubMedCentral
73.
Sozeri B, Gulez N, Ergin M, Serdaroglu E. The experience of canakinumab in renal amyloidosis secondary to familial Mediterranean fever. Mol Cell Pediatr. 2016;3(1):33.CrossRefPubMedPubMedCentral
74.
Ozkan S, Atas B. Canakinumab treatment in four children with colchicine resistant familial mediterranean fever. JPMA J Pak Med Assoc. 2017;67(6):945–7.PubMed
75.
Yazılıtaş F, Aydoğ Ö, Özlü SG, Çakıcı EK, Güngör T, Eroğlu FK, et al. Canakinumab treatment in children with familial Mediterranean fever: report from a single center. Rheumatol Int. 2018;38(5):879–85.CrossRefPubMed
76.
Jesenak M, Hrubiskova K, Kapustova L, Kostkova M, Banovcin P. Canakinumab as monotherapy for treatment of familial Mediterranean fever – first report in central and Eastern Europe region. Bratisl Med J. 2018;119(04):198–200.CrossRef
77.
De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378(20):1908–19.CrossRefPubMed
78.
Trabulus S, Korkmaz M, Kaya E, Seyahi N. Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever. Clin Transpl. 2018;32(8):e13345.CrossRef
79.
Meinzer U, Quartier P, Alexandra J-F, Hentgen V, Retornaz F, Koné-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41(2):265–71.CrossRefPubMed
80.
Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N, et al. Efficacy of Interleukin-1 targeting treatments in patients with familial Mediterranean fever. Inflammation. 2015;38(1):27–31.CrossRefPubMed
81.
Başaran Ö, Uncu N, Çelikel BA, Taktak A, Gür G, Cakar N. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol. 2015;25(4):621–4.CrossRefPubMed
82.
Eroglu FK, Beşbaş N, Topaloglu R, Ozen S. Treatment of colchicine-resistant familial Mediterranean fever in children and adolescents. Rheumatol Int. 2015;35(10):1733–7.CrossRefPubMed
83.
Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35(2):441–6.CrossRefPubMed
84.
85.
Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever. Mod Rheumatol. 2017;27(2):350–5.CrossRefPubMed
86.
Varan O, Kucuk H, Babaoglu H, Atas N, Salman RB, Satis H, et al. Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients. Clin Rheumatol. 2019;38(4):1125–30.CrossRefPubMed
87.
Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol. 2019;29(2):363–6.CrossRefPubMed
88.
McDermott MF. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today Barc Spain 1998. 2009;45(6):423–30.
89.
Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533–41.CrossRefPubMed
90.
Hashkes PJ, Spalding SJ, Hajj-Ali R, Giannini EH, Johnson A, Barron KS, et al. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int. 2014;2014:854842.CrossRefPubMedPubMedCentral
91.
Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol. 2006;24(4):435–7.PubMed
92.
Schattner A, Lachmi M, Livneh A, Pras M, Hahn T. Tumor necrosis factor in familial mediterranean fever. Am J Med. 1991;90(4):434–8.CrossRefPubMed
93.
Schattner A, Gurevitz A, Zemer D, Hahn T. Induced TNF production in vitro as a test for familial Mediterranean fever. QJM Mon J Assoc Physicians. 1996;89(3):205–10.CrossRef
94.
Drenth JP, van Deuren M, van der Ven-Jongekrijg J, Schalkwijk CG, van der Meer JW. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood. 1995;85(12):3586–93.CrossRefPubMed
95.
Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20(9):1544–9.PubMed
96.
Baykal Y, Saglam K, Yilmaz MI, Taslipinar A, Akinci SB, Inal A. Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients. Clin Rheumatol. 2003;22(2):99–101.CrossRefPubMed
97.
Gang N, Drenth JP, Langevitz P, Zemer D, Brezniak N, Pras M, et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol. 1999;26(4):890–7.PubMed
98.
Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95(10):3223–31.CrossRefPubMed
99.
Ozgocmen S, Akgul O. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Mod Rheumatol. 2011;21(6):684–90.CrossRefPubMed
100.
Aldea A, Campistol JM, Arostegui JI, Rius J, Maso M, Vives J, et al. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? Am J Med Genet A. 2004;124A(1):67–73.CrossRefPubMed
101.
Metyas S, Arkfeld D, Forrester D, Ehresmann G. Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. Jcr J Clin Rheumatol. 2004;10(3):134–7.CrossRefPubMed
102.
Kaya S, Kaptanoglu E, Elden H, Hizmetli S. Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept. Intern Med Tokyo Jpn. 2010;49(6):619–22.CrossRef
103.
Ozgocmen S, Özçakar L, Ardicoglu O, Kocakoc E, Kaya A, Kiris A. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol. 2006;25(1):83–7.CrossRefPubMed
104.
Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Care Res. 2005;53(1):146–7.CrossRef
105.
Mor A, Pillinger M, Kishimoto M, Abeles A, Livneh A. Familial Mediterranean fever successfully treated with Etanercept. Jcr J Clin Rheumatol. 2007;13(1):38–40.CrossRefPubMed
106.
Nakamura A, Matsuda M, Tazawa K-I, Shimojima Y, Ikeda S-I. Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Intern Med Tokyo Jpn. 2007;46(15):1247–9.CrossRef
107.
Bilgen SA, Kilic L, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, et al. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol. 2011;17(7):358–62.CrossRefPubMed
108.
Erten S, Erten SF, Altunoglu A. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF. Rheumatol Int. 2012;32(4):1095–7.CrossRefPubMed
109.
Kosmidou M, Mpolotsis V, Christou L, Tsianos EV. Late onset of Crohn’s disease in familial Mediterranean fever: the necessity of anti-TNF treatment. J Dig Dis. 2014;15(2):102–4.CrossRefPubMed
110.
Fujikawa K, Migita K, Tsukada T, Umeda M, Nonaka F, Kawakami A, et al. Interleukin-6 targeting therapy in familial Mediterranean fever. Clin Exp Rheumatol. 2013;31(3 Suppl 77):150–1.PubMed
111.
Hamanoue S, Suwabe T, Hoshino J, Sumida K, Mise K, Hayami N, et al. Successful treatment with humanized anti–interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol. 2016;26(4):610–3.PubMed
112.
Umeda M, Aramaki T, Fujikawa K, Iwamoto N, Ichinose K, Terada K, et al. Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis. Int J Rheum Dis. 2017;20(11):1868–71.CrossRefPubMed
113.
Yilmaz S, Cinar M, Simsek I, Erdem H, Pay S. Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever. Rheumatol Oxf Engl. 2015;54(3):564–5.CrossRef
114.
Nikiphorou E, Neocleous V, Phylactou LA, Psarelis S. Successful use of tocilizumab in two cases of severe autoinflammatory disease with a single copy of the Mediterranean fever gene. Rheumatology. 2017;56(9):1627–8.CrossRefPubMed
115.
Aikawa E, Shimizu T, Koga T, Endo Y, Umeda M, Hori T, et al. Atypical familial Mediterranean fever complicated with gastrointestinal amyloidosis diagnosed due to paroxysmal arthralgia and intractable diarrhea, successfully treated with Tocilizumab. Intern Med. 2019;1:2277–18.
116.
Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067–77.CrossRefPubMed
117.
Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, Bruggner RV, et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol. 2012;30(9):858–67.CrossRefPubMedPubMedCentral
118.
Gök K, Cengiz G, Erol K, Ozgoçmen S. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever. Acta Reumatol Port. 2017;42(1):88–90.PubMed
Metadata
Title
Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
Authors
Georges El Hasbani
Ali Jawad
Imad Uthman
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1201-7

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue

Research

Share and protect our health data: an evidence based approach to rare disease patients’ perspectives on data sharing and data protection - quantitative survey and recommendations

Research

Development of national consensus statements on food labelling interpretation and protein allocation in a low phenylalanine diet for PKU

Research

De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany

Research

Cost-effectiveness analysis of three algorithms for diagnosing primary ciliary dyskinesia: a simulation study

Review

Developmental hypomyelination in Wolfram syndrome: new insights from neuroimaging and gene expression analyses

Research

Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases